LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC.
ALK
Anaplastic Lymphoma Kinase
Lorlatinib
NSCLC
Non–small cell lung cancer
Real-World
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
27
12
2022
revised:
14
02
2023
accepted:
21
02
2023
medline:
20
4
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
Over the past decade, ALK tyrosine kinase inhibitors have delivered unprecedented survival for individuals with Multicenter real-world study of individuals with pretreated advanced The population (N = 38, 10 sites) was heavily pretreated (23 had ≥2 previous treatment lines) with a high disease burden (26 had 2-4 sites and 11 had >4 sites of metastatic disease, 19 had brain metastases). The overall response rate was 44% and the disease control rate was 81%. Lorlatinib dose reduction (18%), interruption (16%), and discontinuation (3%) were consistent with the trial experience. From advanced Lorlatinib is a potent, highly active brain-penetrant third-generation ALK tyrosine kinase inhibitors with benefits for most individuals in the later-line setting in a real-world evaluation, consistent with clinical trial data.
Identifiants
pubmed: 37077199
doi: 10.1016/j.jtocrr.2023.100490
pii: S2666-3643(23)00029-2
pmc: PMC10106481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100490Informations de copyright
© 2023 The Authors.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
JCO Clin Cancer Inform. 2019 Aug;3:1-13
pubmed: 31403818
Science. 2014 Dec 19;346(6216):1480-6
pubmed: 25394791
JTO Clin Res Rep. 2020 Feb 19;1(1):100015
pubmed: 34589917
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
Lancet Oncol. 2017 Jul;18(7):874-886
pubmed: 28602779
J Thorac Oncol. 2021 Dec;16(12):2091-2108
pubmed: 34537440
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
J Thorac Oncol. 2020 Sep;15(9):1484-1496
pubmed: 32360579
J Thorac Oncol. 2020 Mar;15(3):404-415
pubmed: 31756496
Oncologist. 2019 Aug;24(8):1103-1110
pubmed: 30890623
Cancers (Basel). 2017 Sep 05;9(9):
pubmed: 28872581
Mol Cancer Ther. 2021 Sep;20(9):1499-1507
pubmed: 34158340
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
Oncotarget. 2017 Mar 28;8(13):21903-21917
pubmed: 28423535
Cancer Discov. 2018 Jun;8(6):714-729
pubmed: 29650534
Ann Oncol. 2018 Jun 1;29(6):1409-1416
pubmed: 29668860
J Thorac Oncol. 2019 Apr;14(4):691-700
pubmed: 30599201
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40
pubmed: 21502504
Clin Lung Cancer. 2023 Jan;24(1):40-50
pubmed: 36270866
Ann Oncol. 2023 Apr;34(4):339-357
pubmed: 36872130
J Clin Oncol. 2018 Aug 1;36(22):2251-2258
pubmed: 29768118
Cancer Med. 2022 Aug;11(15):2944-2956
pubmed: 35437925
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
J Natl Compr Canc Netw. 2022 May;20(5):497-530
pubmed: 35545176
J Thorac Oncol. 2020 Feb;15(2):258-265
pubmed: 31669591
Clin Cancer Res. 2018 Jun 15;24(12):2758-2770
pubmed: 29599410
Clin Cancer Res. 2018 Jun 15;24(12):2771-2779
pubmed: 29563138
Front Oncol. 2022 Aug 08;12:959637
pubmed: 36003760
J Thorac Oncol. 2020 Dec;15(12):1809-1814
pubmed: 33246594
N Engl J Med. 2016 Jan 7;374(1):54-61
pubmed: 26698910
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570